Poor
Not Aligned
Patient Risk:
High
Summary
Multiple statements directly contradict the provided FDA label excerpts, including indication for asthma and prohibited concomitant use with other long-acting beta2-agonists. These are high-importance safety and use-constraint errors.
Category Scores
Accurate Statements
Formoterol fumarate (Formoterol Fumarate Inhalation Solution) is a long-acting beta2-adrenergic receptor agonist that acts locally in the lung as a bronchodilator.
12.1 Mechanism of Action
Formoterol inhalation acts locally in the lung as a bronchodilator.
12.1 Mechanism of Action
Formoterol Fumarate Inhalation Solution is not indicated for relief of acute symptoms, and extra doses should not be used for that purpose.
17 Patient Counseling Information (Acute Exacerbations or Deteriorations)
Patients should not stop using Formoterol Fumarate Inhalation Solution unless told by a healthcare provider because symptoms may get worse.
17 Patient Counseling Information (Appropriate Dosing)
The daily dosage should not exceed one vial twice daily (40 mcg total daily dose).
17 Patient Counseling Information (Appropriate Dosing)
Unsupported Statements
In vitro and animal findings indicate relevance to humans with COPD is known/established.
Label excerpt states the relevance to humans with COPD is unknown.
Contradictions
High
AI Statement
Formoterol is used for asthma.
Label Reference
17 Patient Counseling Information (Serious Asthma-Related Events: Formoterol Fumarate Inhalation Solution is not indicated for the treatment of asthma.)
Low
AI Statement
Formoterol is used for COPD.
Label Reference
Not supported by the provided label excerpts (only a statement that relevance of certain findings to humans with COPD is unknown is included in 12.1).
Low
AI Statement
Foradil is a brand name for formoterol fumarate (DPI).
Label Reference
Not supported or contradicted by the provided label excerpts.
Low
AI Statement
Oxis is a brand name for formoterol.
Label Reference
Not supported or contradicted by the provided label excerpts.
Low
AI Statement
Formoterol is marketed as a standalone inhaler/solution (formoterol alone).
Label Reference
Not supported or contradicted by the provided label excerpts (only counseling statements for Formoterol Fumarate Inhalation Solution are provided).
Low
AI Statement
Formoterol is marketed as a combination product paired with an inhaled corticosteroid (ICS) such as budesonide.
Label Reference
Not supported or contradicted by the provided label excerpts.
Medium
AI Statement
In vitro and animal findings indicate relevance to humans with COPD is known/established.
Label Reference
12.1 Mechanism of Action (states relevance of in vitro/animal findings to humans with COPD is unknown).
High
AI Statement
Formoterol Fumarate Inhalation Solution should be used as monotherapy without an inhaled corticosteroid to increase safety regarding serious asthma-related events.
Label Reference
17 Patient Counseling Information (Serious Asthma-Related Events: increased risk when used as monotherapy without an inhaled corticosteroid; also states not indicated for asthma treatment).
High
AI Statement
Formoterol Fumarate Inhalation Solution should be used in conjunction with other inhaled medications containing long-acting beta2-agonists.
Label Reference
17 Patient Counseling Information (Concomitant Therapy: should not be used in conjunction with other inhaled medications containing long-acting beta2-agonists).
Important Omissions
FDA label sections for contraindications, boxed warnings, warnings/precautions, adverse reactions, monitoring, and drug interactions were not provided in the input; thus these cannot be evaluated.
Importance:
Moderate
Approved indications are not provided in the supplied excerpt (only counseling statements are provided), so COPD indication accuracy cannot be fully confirmed from the prompt’s label text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response includes multiple statements that conflict with provided label safety/use constraints (e.g., asthma use/indication statements and prohibited concomitant use with other long-acting beta2-agonists).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Conflicts with label: claims that it is used for asthma and recommends/implies contraindicated concomitant long-acting beta2-agonist use.
Suggested Improvement
Remove label-contradicted claims (especially asthma use/indication and concomitant long-acting beta2-agonist use). Restrict descriptions to what is supported by the provided excerpts (MOA/local lung bronchodilator action; administration and dosing/counseling limits).